IMUNON Secures $7 Million in Registered Direct Offering to Advance Phase 3 DNA-Mediated Immunotherapy
Key Insights
IMUNON, Inc. completed a $7 million registered direct offering with a healthcare-focused institutional investor to fund its Phase 3 DNA-mediated immunotherapy (search) development.
The offering includes 1,939,114 shares of common stock and warrants priced at $3.61 per unit, with warrants exercisable at $3.482 per share for five years.
The biotechnology company focuses on innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across human diseases.
IMUNON, Inc. (Nasdaq: IMNN) announced the completion of a $7 million registered direct offering on December 30, 2025, securing funding from a single healthcare-focused institutional investor to advance its Phase 3 DNA-mediated immunotherapy (search) program. The clinical-stage biotechnology company sold 1,939,114 shares of common stock together with warrants to purchase an equivalent number of shares.
Offering Structure and Terms
The securities purchase agreement includes shares priced at $3.61 per unit, with each unit consisting of one share of common stock and one warrant to purchase an additional share. The warrants carry an exercise price of $3.482 per share, are exercisable immediately upon issuance, and will expire five years from the date of issuance. Pre-funded warrants are also available at $3.6099 per unit with an exercise price of $0.0001 per share and no expiration date.
Maxim Group LLC (search) served as the lead placement agent for the offering, with Brookline Capital Markets (search), a division of Arcadia Securities, LLC (search), acting as co-placement agent. The offering is expected to close on or about December 31, 2025, subject to satisfaction of customary closing conditions.
Regulatory Framework
The securities are being offered under a "shelf" registration statement on Form S-3 (File No. 333-279425) that was declared effective by the U.S. Securities and Exchange Commission on May 22, 2024. A prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC, with electronic copies available through the SEC's website and Maxim Group LLC (search).
Company Focus and Development Pipeline
IMUNON describes itself as a clinical-stage biotechnology company focused on advancing innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases. This approach represents what the company characterizes as a differentiating strategy from conventional therapies.
The company is currently in Phase 3 development with its DNA-mediated immunotherapy (search), though specific details about the therapeutic target, patient population, or clinical endpoints were not disclosed in the announcement.
Financial Implications and Risk Factors
The gross proceeds from the offering are expected to be approximately $7.0 million before deducting placement agents' fees and other estimated offering expenses. The company has acknowledged several risk factors in its forward-looking statements, including potential challenges with Nasdaq listing compliance, uncertainties in clinical trial outcomes, and the significant expense and risk associated with conducting clinical trials.
IMUNON noted that interim clinical results are not necessarily indicative of final results and highlighted the uncertainties and difficulties in analyzing interim clinical data. The company also emphasized the need to evaluate its future development plans as it progresses through clinical development.